Type 1 Diabetes | CHOP Research Institute

Type 1 Diabetes

The goal of this Phase 2 study is to assess safety and efficacy of frexalimab to preserve β-cell function in participants with newly diagnosed type 1 diabetes (T1D).

The purpose of this study is to evaluate the safety and pharmacokinetics (drug levels in the blood) of teplizumab in children less than 8 years old.

This study will evaluate the safety and effectiveness of the MiniMed 780G insulin pump system used in combination with the DS5 CGM in type 1 diabetic pediatric participants in a home setting.

Published on
Jan 11, 2023
Diversity Fellow Alfonso Floyd, PhD, studies the impact of risk and resilience on the mental health of minority youth with type 1 diabetes.
Published on
Jun 2, 2022
CHOP and Penn researchers discussed the latest findings about the mechanisms of immunity at the CHOP Research Institute 2022 Scientific Symposium.
Published on
Sep 3, 2021
This week’s In the News highlights two new studies, a new grant, the new director of the Cystic Fibrosis Center, and a physician’s new role.

PRONTO-PEDS will test if a ultra-fast insulin product given before or immediately after meals improves glycemic control in children and teens with type 1 diabetes.

This is a study that investigates whether an IV medication (teplizumab) will slow or halt the progression of type 1 diabetes in children and adolescents (ages 8 - 17 years).

Dr. Weber is a clinical researcher focused on improving bone health in children. He is currently focused on investigating the effects of effects of type 1 diabetes and Duchenne muscular dystrophy on the skeleton. 

weberd [at] chop.edu
Published on
May 28, 2020
Michael Silverman, MD, PhD, is pursuing research to learn how gut bacteria may help signal genes to prevent type 1 diabetes.